Massachusetts, which adopted the nation’s first pulmonary hypertension (PH) law in January, has named the first members of an expert task force dealing with PH patient care. The PH law, signed by Massachusetts Gov. Charlie Baker, requires the state to establish the task force to monitor and report on research, transplants, public awareness,…
A simple test with cord blood could predict which babies are at risk of developing a severe lung disease called bronchopulmonary dysplasia-associated pulmonary hypertension (BPD-PH), according to a study. If scientists can validate the test’s predictive ability, doctors could intervene to try to prevent the disease immediately after a baby is…
The European Medicines Agency (EMA) has completed its review of Uptravi (selexipag) and concluded that doctors may continue prescribing the drug to treat pulmonary arterial hypertension (PAH), according to a press release. The 28-member European Union approved Uptravi for treating PAH in May 2016. However, after…
Due to regulatory delays, the U.S. launch of United Therapeutics‘s implanted pump system for the delivery of Remodulin (treprostinil) for patients with pulmonary arterial hypertension (PAH) will be postponed until 2018. “United Therapeutics’ commitment to bringing better therapies to patients transcends temporary delays or setbacks,” Martine Rothblatt, PhD,…
Northwestern Medicine’s Pulmonary Vascular Disease Program has won accreditation as a Comprehensive Care Center by the Pulmonary Hypertension Association (PHA), in recognition of its excellence in diagnosis, research and clinical care of PH patients. To earn the accreditation, the program, which is led by Stuart Rich,…
England’s National Health Service (NHS) has added three treatments to the options it offers patients with rare diseases, one of which is for pulmonary arterial hypertension (PAH). The additions will help up to 145 people annually. NHS England will cover the cost of doctors performing them. NHS approved 19 treatments in…
Apollo Therapeutics has approved £8.5 million ($10.6 million) to fund four projects, including a small and large molecule discovery program to treat pulmonary arterial hypertension (PAH). Professors Martin Wilkins and Lan Zhao of Imperial College London‘s Department of Medicine will head the PAH program. Both have previously identified a gene called…
The European Medicines Agency (EMA) is reviewing the safety of Uptravi (selexipag) after the deaths of five patients with pulmonary arterial hypertension (PAH) who took the medicine in France. The European Union approved Uptravi for the treatment of PAH in May 2016. The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) will re-examine all…
Terrence Jenkins, second-year celebrity ambassador of the Pulmonary Hypertension Association (PHA), will appear in a print and digital public service ad campaign throughout 2017 to raise awareness about pulmonary hypertension (PH). Jenkins, better known as “Terrence J,” knows firsthand some of the frustrations of battling a rare disease like…
The Pulmonary Hypertension Association (PHA) will present two abstracts with data from the PHA registry, which collects information on pulmonary hypertension (PH) patients diagnosed and evaluated at PHA-accredited centers with the goal of improving their care. The presentations will be given at the American Thoracic Society meeting set for May.
Actelion, which manufactures treatments for conditions like pulmonary arterial hypertension (PAH), will be acquired by Johnson & Johnson for $30 billion. The board of directors of both companies agreed to the transaction, said Alex Gorsky, chairman and CEO of Johnson & Johnson. “We believe this transaction offers compelling…
Bayer and Merck recently presented positive results from five data sets that evaluated the clinical benefits of Adempas (riociguat) for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). The findings were presented at the 11th annual World Congress of the Pulmonary Vascular…
Get regular updates to your inbox.